20 November2026: Innovent Biologics announced that Takeda has received SAKIGAKE designation from the MHLW for its TAK-921
Takeda Pharmaceutical received SAKIGAKE designation from MHLW for TAK-921 for CLDN18.2-positive, unresectable, advanced or recurrent gastric/gastroesophageal junction adenocarcinoma that has progressed after chemotherapy. the designation provides eligibility for priority regulatory consultation and priority review in Japan
The designation is supported by the registrational Phase III G-HOPE-001trial, which evaluated TAK-921 in previously treated patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma. according to Innovent, the trial demonstrated statistically significant and clinically meaningful improvements in both PFS and OS, with a favourable safety profile
The therapy addresses an unmet need in previously treated patients with advanced or recurrent CLDN18.2-positive gastric/GEJ cancer, where second-line treatment outcomes remainpoor and mOS is generally less than 10 months.SAKIGAKE designation supports accelerated development of a targeted treatment option for this patient population in Japan
TAK-921 is a CLDN18.2-targeted ADC that selectively delivers a highly potent topoisomerase I inhibitor payload to CLDN18.2-expressing tumour cells through a cleavable linker, inducing tumour-cell death. Its Fc-silencing design is intended to minimize off-target toxicity outside the tumour
The designation strengthens the collaboration between Innovent and Takeda and advances the international development of IBI343, described by Innovent as the first CLDN18.2-targeted ADC to enter regulatory review. the drug has also received two BTD in China for advanced gastric and pancreatic cancers, while its gastric cancer marketing application is under priority review by China’s NMPA